Twist Bioscience (TWST) operating margin

Operating margin · fiscal 2025
-36.2%

Twist Bioscience (TWST) had an operating margin of -36.2% in fiscal 2025 (the year ended September 30, 2025). That is 20.0 percentage points higher than the -56.2% of fiscal 2024. Figures as of 17 Nov 2026, 21:02 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-36.2%
Change on fiscal 2024
+20.0 pts
Highest on record
-36.2%fiscal 2025
Lowest on record
-543.2%fiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Twist Bioscience operating margin, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was -36.2% in fiscal 2025 and the lowest -543.2% in fiscal 2017. The fiscal 2025 figure is higher than in every one of the 8 earlier fiscal years on record, whose median is -138.9%.

Gross margin was 50.7% in fiscal 2025. Net margin was -20.6% in fiscal 2025.

History · 9 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Gross margin
  • Net margin

Twist Bioscience operating margin, year by year

Twist Bioscience (TWST) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedGross marginNet margin
2025-36.2% 20.0 pts up50.7%-20.6%
2024-56.2% 28.2 pts up42.6%-66.7%
2023-84.4% 37.9 pts up36.6%-83.5%
2022-122.3% 6.9 pts down41.4%-107.0%
2021-115.4% 40.1 pts up—-114.9%
2020-155.5% 44.7 pts up—-155.3%
2019-200.1% 77.3 pts up—-198.0%
2018-277.5% 265.7 pts up—-280.2%
2017-543.2%——-550.8%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

Operating margin at health care companies of similar size

Operating margin of Twist Bioscience and comparable companies
CompanyOperating marginFiscal year
TG Therapeutics TGTX20.0%2025
Praxis Precision Medicines PRAX-2340.3%2024
Twist Bioscience TWST-36.2%2025
Protagonist Therapeutics PTGX-343.6%2025
Krystal Biotech KRYS41.5%2025
10x Genomics TXG-17.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TWST

Twist Bioscience, figure by figure

Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value

Twist Bioscience operating margin: questions and answers

What is Twist Bioscience's operating margin?

Twist Bioscience (TWST) had an operating margin of -36.2% in fiscal 2025 (the year ended September 30, 2025). That is 20.0 percentage points higher than the -56.2% of fiscal 2024.

Is Twist Bioscience's operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 8 earlier fiscal years on record, whose median is -138.9%.

What are the highest and lowest operating margin figures on record for Twist Bioscience?

Across the 9 fiscal years on record (2017–2025), the highest was -36.2% in fiscal 2025 and the lowest -543.2% in fiscal 2017.

What are Twist Bioscience's gross and net margins?

Gross margin was 50.7% in fiscal 2025. Net margin was -20.6% in fiscal 2025.

How is Twist Bioscience's operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Twist Bioscience (TWST) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/TWST/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.